BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nventa Biopharmaceuticals Corporation (NVN.TO) Appoints John Varian to Board of Directors


5/7/2008 9:37:40 AM

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today the appointment of John Varian to the company's board of directors. Mr. Varian currently serves as the chief operating officer and chief financial officer of Aryx Therapeutics, a pharmaceutical company focused on the discovery and development of oral therapeutics for chronic disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are very pleased to welcome John to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His extensive experience in helping companies establish strategic direction, raise venture and public capital, and negotiate successful alliances and acquisitions should be extremely beneficial to Nventa as it grows internally and continues its path to commercializing its first product."

Prior to joining Aryx Therapeutics, Mr. Varian was chief financial officer of Genset S.A., where he was a key member of the team negotiating the company's sale to Serono S.A. in 2002. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation's chief financial officer from June 1997 until October 1998. Mr. Varian is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference.

"I am proud to join the board at Nventa Biopharmaceuticals, a truly innovative company that is working to bring much needed therapeutic options to patients affected by HPV-related diseases," stated Mr. Varian. "As someone who has long been closely involved in the drug discovery and development industry, I believe that by sharing my expertise with the company, I can play a role in supporting its ongoing success."

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.



CONTACT: Donna Slade, Director, Investor Relations, of Nventa
Biopharmaceuticals Corporation, +1-858-202-4945, dslade@nventacorp.com; or
media, Tim Brons of Vida Communication, +1-415-675-7402,
tbrons@vidacommunication.com, for Nventa Biopharmaceuticals Corporation;
Michael Moore, the Equicom group, +1-416-815-0700, ext. 241

Web site: http://www.nventacorp.com/


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->